[1].HIV感染女性避孕方法选择的中国专家共识[J].中国计划生育和妇产科,2020,(5):3-8.
点击复制

HIV感染女性避孕方法选择的中国专家共识
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2020年5期
页码:
3-8
栏目:
专家共识
出版日期:
2020-05-25

文章信息/Info

作者:
中华医学会计划生育学分会
关键词:
HIV感染; 避孕方法; 专家共识; 女性
分类号:
R 183;R 169.41

参考文献/References:

［1］UNAIDSUNAIDS data 2019 ［R/OL］.［20190516］.https://www.unaids.org/en/resources/documents/2019/2019UNAIDSdata. ［2］陈方方，郭巍，秦倩倩，等．我国20102016年新发现15岁及以上女性艾滋病病毒感染者及艾滋病患者的时空分布特征 ［J］．中华流行病学杂志，2018，39（6）：739744． ［3］UNAIDS. Together we will end AIDS ［R/OL］.［20120725］.http://files.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2012/JC2296_UNAIDS_TogetherReport_2012_en.pdf ［4］温莹，乔亚萍，苏穗青，等．我国部分地区HIV感染育龄妇女避孕咨询指导服务能力及开展现状 ［J］．中国艾滋病性病，2015，21（5）：381384． ［5］UNAIDS.UNAIDS data 2006［R/OL］.［20060706］. http：//www.who.int/hiv/mediacenter/200605FS_global facts figures_en.pdf. ［6］World Health Organization.(2015).Medical eligibility criteria for contraceptive use, 5th ed.World Health Organization. ［R/OL］https://apps.wh o.int/iris/handle/10665/181468. ［7］World Health Organization. Department of reproductive health and research ［Z］.2005. ［8］Chakrapani V, Newman P A, Murali S, et al. Prevalence and contexts of inconsistent condom use among heterosexual men and women living with HIV in India: implications for prevention ［J］. AIDS Patient Care and STDs, 2010, 24(1): 4958. ［9］UNFPA. Media Fact Sheet: Comprehensive Condom Programming［EB/OL］.New York:UNFPA,20100701］.https://www.unfpa.org/webdav/site/global/shared/factsheets/media_fact_sheet_condoms.pdf. ［10］Allen S, Stephenson R, Weiss H, et al. Pregnancy, hormonal contraceptive use, and HIVRelated death in Rwanda ［J］. Journal of Women's Health, 2007, 16(7): 10171027. ［11］Chelsea B P, Maria J W, Kiwanuka N, et al. Effect of hormonal contraceptive use on HIV progression in female HIV seroconverters in Rakai, Uganda ［J］. AIDS, 2010, 24(12): 19371944. ［12］Morrison C S, PaiLien C, Nankya I, et al. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe ［J］. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011, 57(2): 157164. ［13］Heffron R, Mugo N, Ngure K, et al. Hormonal contraceptive use and risk of HIV1 disease progression ［J］. AIDS, 2013, 27(2): 261267. ［14］Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV1 transmission: a prospective cohort study ［J］. Lancet Infectious Diseases, 2012, 12(1): 1926. ［15］Lutalo T, Musoke R, Kong Xiangrong, et al. Effects of hormonal contraceptive use on HIV acquisition and transmission among HIVdiscordant couples ［J］. AIDS, 2013, 27(Suppl 1): S 27S 34. ［16］Bengtson A, Kwok C, Robert A S, et al. Hormonal contraceptive use and discontinuation among HIVInfected women in Uganda and Zimbabwe ［J］. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013, 63(4): 506513. ［17］Lauren J R, Sandra I M, Shiu K, et al. Hormonal contraceptive use and women's risk of HIV acquisition: a metaanalysis of observational studies ［J］. The Lancet Infectious Diseases, 2015, 15(2): 181189. ［18］Chelsea B P, Kathryn M C. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence ［J］. The Lancet Infectious Diseases, 2013, 13(9): 797808. ［19］Chinula L, Nelson J E, Wiener J, et al. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial ［J］. Contraception, 2018, 98(3): 193198. ［20］ECHO Consortium. ECHO finds no substantial difference in HIV risk among DMPAIM,Copper IUD,and LNG implant users ［EB/OL］［20200409］. http://echoconsortium.com/wpcontent/uploads/2019/06/CONFIDENTIAL_ECHO_release_13June2019_FINAL2.pdf. ［21］Cohn S E, Park J G, Watts D H, et al. Depomedroxyprogesterone in Women on Antiretroviral Therapy: Effective Contraception and Lack of Clinically Significant Interactions ［J］. Clinical Pharmacology & Therapeutics, 2007, 81(2): 222227. ［22］Nanda K, Amaral E, Hays M, et al. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy ［J］. Fertility and Sterility, 2008, 90(4): 965971. ［23］Haddad L B, Cwiak C, Jamieson D J, et al. Contraceptive adherence among HIVinfected women in Malawi: a randomized controlled trial of the Copper intrauterine device and depot medroxyprogesterone acetate ［J］. Contraception, 2013, 88(6): 737743. ［24］Taneepanichskul S, Intaraprasert S, Phuapradit W, et al. Use of norplant implants in asymptomatic HIV1 infected women ［J］. Contraception, 1997, 55(4): 205207. ［25］David H, Jennifer L, James K, et al. Effect of concurrent use of antiretroviral therapy and levonorgestrel subdermal implant for contraception on CD4 counts: a prospective cohort study in Kenya ［J］. Journal of the International AIDS Society, 2013, 16(1): 18448. ［26］Patel R C, Onono M, Gandhi M, et al. Pregnancy rates in HIVpositive women using contraceptives and efavirenzbased or nevirapinebased antiretroviral therapy in Kenya: a retrospective cohort study ［J］. The Lancet HIV, 2015, 2(11): e 474e 482. ［27］Carolina S V, Bahamondes M V, Roberto M S, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on EtonogestrelReleasing implant pharmacokinetics in HIVPositive women ［J］. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014, 66(4): 378385. ［28］Kimberly K S, Kristin M D, Shadia Nakalema, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenzbased antiretroviral therapy: a ThreeArm pharmacokinetic evaluation over 48 weeks ［J］. Clinical Infectious Diseases, 2016, 62(6): 675682. ［29］Castellsagué X, Díaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies ［J］. The Lancet Oncology, 2011, 12(11): 10231031. ［30］Buhling K J, Nikki B Z, Lotke P, et al. Worldwide use of intrauterine contraception: a review ［J］. Contraception, 2014, 89(3): 162173. ［31］吴尚纯，邹燕．宫内节育器应用现状与研究进展 ［J］．中国实用妇科与产科杂志，2009，25（10）：795797． ［32］Mitchell H S, Stephens E. Contraception choice for HIV positive women ［J］. Sexually Transmitted Infections, 2004, 80(3): 167173. ［33］Morrison C S, SekaddeKigondu C, Samuel K S, et al. Is the intrauterine device appropriate contraception for HIV1infected women ［J］. British Journal of Obstetrics and Gynaecology, 2001, 108(8): 784790. ［34］Heikinheimo O, Lehtovirta P, Suni J, et al. The levonorgestrelreleasing intrauterine system (LNGIUS) in HIVinfected women—effects on bleeding patterns, ovarian function and genital shedding of HIV ［J］. Human Reproduction, 2006, 21(11): 28572861. ［35］Lehtovirta P,Paavonen J,heikinheimo O.Experience with the levonorgestrelreleasing intrauterine system among HIVinfected women ［J］. Contraception, 2007, 75(1): 3739. ［36］Heikinheimo O, Lehtovirta P, Aho I, et al. The levonorgestrelreleasing intrauterine system in human immunodeficiency virus–infected women: a 5year followup study ［J］. American Journal of Obstetrics and Gynecology, 2011, 204(2): 126.e 1126.e 4. ［37］Martina L B, Lathrop E, Haddad L B, et al. Reproductive healthcare needs and desires in a cohort of HIVPositive women ［J］. Infectious Diseases in Obstetrics and Gynecology, 2012,2012:107878. ［38］Massad L S, Evans C T, Wilson T E, et al. Contraceptive use among U.S. women with HIV ［J］. Journal of Women's Health (2002), 2007, 16(5): 657666. ［39］Raziano V T, Smoots A N, Haddad L B, et al. Factors associated with sterilization among HIVpositive US women in an urban outpatient clinic ［J］. AIDS Care, 2017, 29(5): 612617. ［40］Francesca T A, Rosenkranz S L, Segal Y, et al. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine ［J］. AIDS, 2006, 20(14): 18331841. ［41］Kearney B P, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives ［J］. Pharmacotherapy, 2009, 29(8): 924929. ［42］Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIVInfected women ［J］. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002, 29(5): 471477. ［43］Nanda K, DelanyMoretlwe S, Dubé K, et al. Nevirapinebased antiretroviral therapy does not reduce oral contraceptive effectiveness ［J］. AIDS, 2013, 27(Suppl 1): S 17S 25. ［44］Landolt N K, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives ［J］. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013, 62(5): 534539. ［45］Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIVnegative women ［J］. Antiviral Therapy, 2011, 16(2): 149156. ［46］Kreitchmann R,Innocente A P,Preussler G M, et al.efficacy of contraceptive implants for HIVinfected women in Porto Alegre. Brazil ［J］. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 2012, 117(1): 8182. ［47］Perry S H, Swamy P, Preidis G A, et al. Implementing the jadelle implant for women living with HIV in a resourcelimited setting: concerns for drug interactions leading to unintended pregnancies ［J］. AIDS (London, England), 2014, 28(5): 791793. ［48］Pyra M, Heffron R, Nelly R M, et al. Effectiveness of hormonal contraception in HIVinfected women using antiretroviral therapy ［J］. AIDS, 2015, 29(17): 23532359. ［49］Vogler M A, Patterson K, Lori K, et al. Contraceptive efficacy of oral and transdermal hormones when CoAdministered with protease inhibitors in HIV1Infected women: pharmacokinetic results of ACTG trial a5188 ［J］. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010, 55(4): 473482. ［50］Atrio J, Stanczyk F Z, Neely M,et al. Effect of protease inhibitors on SteadyState pharmacokinetics of oral norethindrone contraception in HIVInfected women ［J］. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014, 65(1): 7277. ［51］Anderson M S, William D H, Allison R M,et al.Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women ［J］. British Journal of Clinical Pharmacology,2011, 71(4): 616620.

相似文献/References:

[1]陈晓勤,雷贞武,谢黎,等.三种避孕方法对妇女血清铁蛋白影响的研究[J].中国计划生育和妇产科,2009,(06):0.
　CHEN Xiao-qin,LEI Zhen-wu,XIE Li,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(5):0.
[2]曾梦艳,廖滔.HIV感染孕产妇剖宫产48例情况分析[J].中国计划生育和妇产科,2009,(06):0.
[3]周燕飞,陈智慧,范幸,等.长沙市女性人工流产及避孕现状调查[J].中国计划生育和妇产科,2014,(04):0.
　ZHOU Yan-fei,CHEN Zhi-hui,FAN Xing,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(5):0.
[4]陈静,邱骏,滕银成,等.异位妊娠与避孕方法使用的相关性分析[J].中国计划生育和妇产科,2015,(05):0.
　CHEN Jing,QIU Jun,TENG Yin-cheng,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2015,(5):0.

更新日期/Last Update: 2020-05-25